Market Overview

Rodman & Renshaw Reiterates Cytokinetics Market Outperform, $4 PT

Share:

Rodman & Renshaw reiterated its Cytokinetics (NASDAQ: CYTK) Market Outperform rating and $4 price target in a research report published today.

Posted-In: Price Target Reiteration Analyst Ratings

 

Related Articles (CYTK)

Get Benzinga's Newsletters